Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.